No Data
Shanghai Universal Biotech Co.,Ltd.'s (SZSE:301166) Shares May Have Run Too Fast Too Soon
As of the end of June, Hangzhou Antibody Research Center has developed more than 1900 SPU products.
On September 13th, Guo Longhui reported that Unilovo (301166.SZ) held a performance briefing on September 13, 2024. Regarding the question, "What new investments or collaborations does Unilovo have in product research and development?", the company stated that as of the end of June 2024, the Hangzhou Antibody R&D Center has accumulated over 1900 SPU (Standard Packaging Unit) for the research and development of products (IVD antibodies, pathological IHC antibodies, companion diagnostic antibodies, etc.). The Nanjing Protein R&D Center has accumulated over 1500 SPU for the research and development of products (drug targets, cytokines, etc.). The company's proprietary brand products have further enriched.
Youniwei (301166.SZ): The US biotechnology bill has no direct impact on the company's business temporarily.
Gelonghui September 10th｜Youninwei (301166.SZ) stated on the investor interaction platform that the company mainly targets domestic universities, research institutes, hospitals, biomedical enterprises, etc., providing biological reagents and related instruments, consumables, and comprehensive technical services related to life sciences. As of now, the company's production operation is normal, and the US Biotechnology Act has no direct impact on the company's business at the moment.
UNI-INOV (301166.SZ): cumulatively repurchased 0.41% of shares.
On September 2nd, Gelonghui announced that as of August 31, 2024, the company has repurchased a total of 355,400 shares of the company through the stock repurchase special securities account through centralized auction trading, accounting for 0.41% of the total share capital of the company. The highest fill price is 30 yuan/share, the lowest fill price is 25.36 yuan/share, and the total amount paid is 9,654,933 yuan (excluding transaction costs).
Unionway: 2024 Semi-Annual Report
Unionway: 2024 Semi-Annual Report Summary
Shanghai Universal BiotechLtd (SZSE:301166) Is Reinvesting At Lower Rates Of ReturnNo Data
No Data
